orforglipron
Sign in to saveOrforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.
Wikidata facts
- Mass
- 882.377721076
Show 4 more facts
- Commons category
- Orforglipron
- isomeric SMILES
- Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4nc(=O)o[nH]4)C[C@@H]2C)CC3)cc(C)c1F
- chemical formula
- C₄₈H₄₈F₂N₁₀O₅
- canonical SMILES
- Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)C(C)N(C(=O)c2cc4cc(C5CCOC(C)(C)C5)ccc4n2C2(c4nc(=O)o[nH]4)CC2C)CC3)cc(C)c1F
via Wikidata · CC0
~3 min read
Article
6 sectionsContents
- Mechanism of action
- Clinical trials
- Phase III ACHIEVE-1 trial
- See also
- References
- External links
Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.
Orforglipron is easier to produce than existing peptide GLP-1 agonists and is expected to be cheaper.
Connections
metformin
Entity
tirzepatide
Entity
anti-diabetic medication
Entity
alogliptin
Entity
tadalafil
Entity
empagliflozin
Entity
linagliptin
Entity
insulin glargine
Entity
small molecule
Entity
baricitinib
Entity
glucagon-like peptide-1 agonist
Medication
Insulin Lispro
Entity
dulaglutide
Entity
glucagon
Entity
ertugliflozin
Entity
obesity
Entity
diarrhea
Entity
digital object identifier
Entity
chemical formula
Entity
insulin
Entity
Categories
Anti-obesity drugsChemical articles with multiple CAS registry numbersChemical articles with multiple PubChem CIDsChemicals using indexlabelsCyclopropanesDrugs not assigned an ATC codeFluoroarenesGLP-1 receptor agonistsImidazolesIndazolesMultiple chemicals in Infobox drugOxadiazolesPyrazolopyridines